Growth hormone secretagogue · Also known as Pralmorelin, KP-102, Growth Hormone Releasing Peptide-2
A synthetic six-amino acid peptide that stimulates growth hormone release by activating the ghrelin receptor (GHS-R1a). It was the first growth hormone secretagogue introduced into clinical use and is approved in Japan as a diagnostic agent for GH deficiency.
GHRP-2 has been studied in numerous human clinical trials spanning decades, including studies in GH-deficient children and healthy adults. It is approved in Japan under the brand name Pralmorelin for diagnosing adult and pediatric growth hormone deficiency. Among the GHRP family, it is considered the most potent for GH stimulation while producing fewer appetite-related side effects than GHRP-6.
GHRP-2 acts as a ghrelin receptor (GHS-R1a) agonist on pituitary somatotrophs, triggering a potent release of growth hormone. It works through a different mechanism than GHRH, activating phospholipase C and increasing intracellular calcium rather than using the cAMP pathway. This means GHRP-2 and GHRH have synergistic effects when used together, producing GH responses greater than the sum of their individual effects.
Beyond its pituitary action, GHRP-2 also stimulates hypothalamic GHRH neurons and suppresses somatostatin release, amplifying its GH-releasing effect. Clinical studies show peak GH levels of 30-100 ng/mL within 15-30 minutes of subcutaneous injection, representing 8-20 fold increases over baseline. Unlike ipamorelin, GHRP-2 produces mild stimulation of ACTH, cortisol, and prolactin, though these effects are less pronounced than with hexarelin or GHRP-6.
100 mcg/day subcutaneous
Weeks 1-2100-300 mcg 1-3x daily subcutaneous
8-12 week cyclesMost side effects tend to improve as your body adjusts.